Compositions and methods for cancer immunotherapy
US9770467B2 · kind B2 · utility
29Cited by
21References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 7, 2013 |
| Grant date | Sep 26, 2017 |
| Priority date | — |
| Expiry date | Oct 30, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a combination therapy which relies on a small molecule immune stimulator—cyclic-di-nucleotide (CDN)—that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes) formulated with allogeneic human tumor cell lines engineered to secrete high amounts of GM-CSF. This combination therapy can provide an ideal synergy of multiple tumor associated antigens, DC recruitment and proliferation, coupled with a potent DC activation stimulus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.